Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2015 08:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at Stifel 2015 Healthcare Conference

BURLINGTON, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the...
November 09, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Third-Quarter 2015 Financial Results

Recent Highlights Secured a notice of allowance for the trademark Zilretta™ (previously known as FX006) from the United States Patent and Trademark Office (U.S. PTO)Advanced Zilretta™, company’s...
November 02, 2015 08:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Third-Quarter 2015 Financial Results on November 9, 2015

BURLINGTON, Mass., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its third-quarter 2015...
September 08, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006

− FX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo − Conference call scheduled for tomorrow,...
September 01, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Granted Fast Track Status by the FDA for FX006 for Treatment of Osteoarthritis of the Knee

BURLINGTON, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...
August 06, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Second-Quarter 2015 Financial Results

Recent Highlights Advanced FX006, company's lead program, for the treatment of moderate to severe osteoarthritis (OA) pain by completing patient enrollment in Phase 3 clinical trial ahead...
August 04, 2015 16:02 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Secures $30 Million in Debt Financing

Non-dilutive debt financing provides funding for manufacturing expansion for company's Phase 3 lead clinical candidate, FX006, for moderate to severe osteoarthritis (OA) pain BURLINGTON,...
August 04, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Expands Supply Capacity for FX006 by Entering Into Agreement With Patheon

- Adding Patheon as a contract manufacturer, in addition to Evonik Corporation, bolsters manufacturing capacity for planned commercialization of company's lead program BURLINGTON, Mass., Aug. 4,...
July 30, 2015 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Second-Quarter 2015 Financial Results on August 6, 2015

BURLINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its second-quarter 2015...
July 29, 2015 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Completes Enrollment in Phase 3 Clinical Trial With Lead Compound FX006 in Patients With Osteoarthritis of the Knee

With rapid enrollment in Phase 3 trial, the company expects to report topline data in first quarter of 2016, ahead of schedule Topline data from ongoing pivotal Phase 2b clinical trial also...